Acute Myocardial Infarction

1. Clinical Overview

Summary

Acute myocardial infarction (AMI) represents myocardial cell death (necrosis) due to prolonged ischemia, typically resulting from acute coronary artery occlusion. [1] The condition remains a leading cause of morbidity and mortality worldwide, affecting over 500,000 people annually in the United States alone. [2] The pathophysiological hallmark is acute disruption of an atherosclerotic plaque with subsequent thrombosis, leading to critical reduction in coronary blood flow. [1,3]

AMI is classified into two principal types based on electrocardiographic findings: ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI). [1] This distinction is critical as it determines immediate management strategy—STEMI mandates emergent reperfusion therapy (primary percutaneous coronary intervention [PCI] or fibrinolysis) within minutes to hours, whereas NSTEMI requires urgent but not necessarily immediate invasive management. [1,4]

The diagnosis rests on three pillars: (1) clinical presentation (typically acute chest pain), (2) electrocardiographic changes, and (3) elevated cardiac biomarkers (troponin). [1] Prompt recognition and rapid reperfusion are paramount—mortality increases exponentially with treatment delay, hence the mantra "time is muscle." [4] Modern management combines immediate pharmacotherapy (dual antiplatelet therapy, anticoagulation, statins), reperfusion strategies, and comprehensive secondary prevention to reduce recurrent events and optimize long-term outcomes. [1,5]

Key Facts

• Definition: Myocardial necrosis due to acute coronary artery occlusion [1]
• Incidence: 500,000-600,000 new cases annually in the US [2]
• In-hospital mortality: STEMI 5-7%, NSTEMI 3-5% (with modern treatment) [2,4]
• 30-day mortality: 10% overall, higher if delayed treatment [2]
• STEMI vs NSTEMI ratio: Approximately 30-40% STEMI, 60-70% NSTEMI [2]
• Peak age: 55-70 years, but can occur at any age with risk factors
• Critical time targets: Door-to-balloon less than 90 minutes for STEMI; door-to-needle less than 30 minutes for fibrinolysis [4]
• Key investigation: 12-lead ECG within 10 minutes of presentation [1,4]
• Definitive biomarker: High-sensitivity cardiac troponin [1,6,7]

Clinical Pearls

"Time is muscle, delay is death" — Every 30-minute delay in STEMI reperfusion increases 1-year mortality by 7.5%. Door-to-balloon time should be less than 90 minutes; door-to-needle less than 30 minutes for fibrinolysis. [4]

"ECG within 10 minutes, troponin doesn't wait" — ECG must be obtained within 10 minutes of presentation. Do NOT wait for troponin results to make reperfusion decisions in STEMI. [1,4]

"STEMI = immediate cath lab; NSTEMI = risk stratify then plan" — STEMI requires immediate reperfusion. NSTEMI requires urgent treatment but timing of angiography (2-24 hours vs 24-72 hours) depends on risk stratification (GRACE/TIMI scores). [1,8]

"Don't forget MONA-B is outdated; think DAPT-S-A" — Modern acute management: Dual antiplatelet therapy, Anticoagulation, Pain relief, Time to reperfusion, Statin, ACE inhibitor/ARB (if indicated). Routine oxygen and morphine are NOT recommended unless specific indications exist. [1,4]

"Troponin rises don't lie, but kinetics reveal the truth" — A single elevated troponin indicates myocardial injury, not necessarily infarction. Serial troponin measurements showing a significant rise (≥20% change) or fall pattern confirm acute MI. [6,7]

"Silent killers: elderly, diabetic, female" — Up to 20-30% of MIs present atypically (dyspnea, fatigue, syncope) without chest pain, particularly in elderly patients, diabetics, and women. Maintain high index of suspicion. [2]

Why This Matters Clinically

AMI is a time-critical emergency where every minute of delay increases myocardial damage, complications, and mortality. Early recognition through systematic ECG acquisition, accurate STEMI/NSTEMI differentiation, and immediate evidence-based therapy can reduce mortality by 30-50%. [1,4] For STEMI, primary PCI within 90 minutes reduces mortality from 15-20% to 5-7%. [4] Understanding troponin kinetics prevents both under-diagnosis of subtle presentations and over-diagnosis of non-ischemic myocardial injury. [6,7] Post-MI risk stratification (GRACE, TIMI scores) guides intensity of invasive and medical therapy, while comprehensive secondary prevention (antiplatelet therapy, statins, ACE inhibitors, beta-blockers, cardiac rehabilitation, lifestyle modification) prevents recurrent events and improves long-term survival. [5,8,9]

---

2. Epidemiology

Incidence & Prevalence

The global burden of AMI remains substantial despite declining age-adjusted incidence in developed countries. [2]

United States Data:

• Annual incidence: Approximately 550,000 new MIs and 200,000 recurrent MIs per year [2]
• Prevalence: ~3% of adults ≥20 years have history of MI [2]
• STEMI: 30-40% of all MIs [2]
• NSTEMI: 60-70% of all MIs [2]

Temporal Trends:

• Age-adjusted incidence declining in developed nations (improved prevention, statin use) [2]
• Case-fatality rates declining (improved acute management, reperfusion strategies) [2]
• Increasing proportion of NSTEMI relative to STEMI (better troponin assays, aging population) [2]

Demographics

Risk Factors

Non-Modifiable:

• Age (most powerful predictor; risk doubles each decade after 40)
• Male sex (prior to menopause)
• Family history (premature CAD: male first-degree relative less than 55 years, female less than 65 years)
• Genetic factors (multiple polygenic risk scores identified)

Modifiable Risk Factors:

Emerging Risk Factors:

• Chronic inflammatory conditions (rheumatoid arthritis, SLE)
• Air pollution exposure
• Sleep apnea
• Depression and chronic stress

Common Presentations

---

3. Pathophysiology

Molecular Pathophysiology

Exam Detail: #### The Atherothrombotic Cascade

Step 1: Atherosclerotic Plaque Formation

• Chronic endothelial injury (hypertension, smoking, diabetes, dyslipidemia)
• LDL oxidation and uptake by macrophages → foam cells
• Inflammatory cytokine release (IL-6, TNF-α, CRP)
• Smooth muscle cell migration and proliferation
• Fibrous cap formation over lipid-rich necrotic core

Step 2: Plaque Vulnerability and Rupture

• Vulnerable plaque characteristics: thin fibrous cap (less than 65 μm), large lipid core (> 40% plaque volume), active inflammation (macrophage infiltration), reduced smooth muscle cells [1,3]
• Triggering factors: hemodynamic stress (morning surge in BP/HR), inflammation, sympathetic activation
• Cap rupture exposes highly thrombogenic subendothelial matrix (collagen, tissue factor, von Willebrand factor)

Step 3: Acute Thrombosis

• Platelet adhesion via GPIb-vWF interaction
• Platelet activation and release of ADP, thromboxane A2, serotonin
• Platelet aggregation via GPIIb/IIIa-fibrinogen cross-linking
• Coagulation cascade activation: tissue factor → Factor VIIa → thrombin generation → fibrin mesh
• Result: Occlusive or subocclusive thrombus [1,3]

Step 4: Myocardial Ischemia and Necrosis

• Cessation of aerobic metabolism within seconds
• Shift to anaerobic glycolysis → lactate accumulation → acidosis
• ATP depletion within minutes
• Loss of membrane ionic gradients (Na+/K+ ATPase failure)
• Calcium overload → myocyte contracture
• Irreversible injury begins at 20-30 minutes of complete occlusion
• "Wavefront phenomenon": necrosis progresses from subendocardium to subepicardium over 3-6 hours [1,3]

Step 5: Myocardial Healing and Remodeling

• Inflammatory phase (0-3 days): neutrophil infiltration, cytokine release
• Proliferative phase (3-14 days): macrophage removal of necrotic tissue, granulation tissue formation
• Maturation phase (14 days-months): collagen deposition, scar formation
• Ventricular remodeling: chamber dilation, wall thinning, compensatory hypertrophy of viable myocardium

STEMI vs NSTEMI: Pathophysiological Distinction

The fundamental difference lies in the degree and duration of coronary occlusion: [1,4]

Why This Distinction Matters Clinically:

• STEMI mandates immediate reperfusion (door-to-balloon less than 90 min) [1,4]
• NSTEMI timing depends on risk stratification: very high risk (0-2h), high risk (2-24h), intermediate risk (24-72h) [1,8]
• Fibrinolysis is ONLY indicated in STEMI (contraindicated in NSTEMI) [4]

Coronary Artery Territories and Infarct Patterns

Special Patterns:

• Posterior MI: ST-depression V1-V3 with tall R waves; confirmed by ST-elevation in posterior leads V7-V9
• RV infarction: Occurs in 30-50% of inferior STEMIs; diagnosed by ST-elevation in V4R; requires volume resuscitation (avoid diuretics/nitrates)
• Wellens syndrome: Deep T-wave inversions in V2-V4 indicating critical LAD stenosis; high risk of extensive anterior STEMI within days

---

4. Clinical Presentation

Symptoms: The Patient's Story

Typical Anginal Presentation (70-80% of cases): [1,2]

• Character: Heavy, pressure-like, crushing, squeezing, "elephant sitting on chest"
• Location: Retrosternal, diffuse across anterior chest
• Radiation: Left arm (most common), jaw, neck, shoulders, right arm, epigastrium, back
• Duration: Persistent (> 20 minutes), waxing and waning pattern suggests ACS
• Onset: Often at rest or with minimal exertion (distinguishes from stable angina)
• Associated symptoms:
  • Diaphoresis (profuse sweating) - highly specific
  • Nausea and vomiting (especially inferior MI - vagal stimulation)
  • Dyspnea (indicates LV dysfunction or pulmonary edema)
  • Lightheadedness, presyncope
  • Sense of impending doom (angor animi)
• Relieving factors: NOT relieved by rest or nitroglycerin (distinguishes from stable angina)

Atypical Presentations (20-30% of cases): [2]

More common in:

• Elderly patients (> 75 years)
• Diabetic patients (autonomic neuropathy)
• Female patients
• Chronic kidney disease
• Post-cardiac transplant (denervated heart)

Atypical symptoms:

• Dyspnea alone (most common atypical presentation) - suggests heart failure or LV dysfunction
• Epigastric pain - often mistaken for GERD or peptic ulcer disease
• Isolated jaw, arm, or back pain
• Fatigue, weakness
• Syncope or presyncope (arrhythmia, cardiogenic shock)
• Acute confusion (especially elderly - reduced cerebral perfusion)
• Painless ischemia (5-10% of all MIs, particularly diabetics)

Signs: Physical Examination

General Appearance:

• Distressed, anxious, restless
• Diaphoretic (cold, clammy skin)
• Pallor
• Position: Often leaning forward or sitting upright (if pulmonary edema present)

Vital Signs:

Cardiovascular Examination:

Respiratory Examination:

• Bibasal crackles: Pulmonary edema (LV failure) - extent correlates with Killip class
• Reduced air entry: Pleural effusion (uncommon, usually small)

Signs of Complications:

⚠️ Red Flag: Immediate Escalation Required:

• Cardiogenic shock: Cold, clammy extremities; altered mental status; SBP less than 90 mmHg; oliguria (less than 0.5 mL/kg/h); lactate > 2 mmol/L
• Acute pulmonary edema: Severe dyspnea, pink frothy sputum, diffuse crackles, oxygen saturation less than 90%
• Mechanical complications: New harsh systolic murmur + sudden hemodynamic deterioration
• Arrhythmia: Sustained VT, VF, complete heart block, symptomatic bradycardia

Red Flags

[!CAUTION] RED FLAGS — Immediate Assessment and Intervention:

• Cardiogenic shock (SBP less than 90 mmHg, cold extremities, altered mental status) — Consider mechanical circulatory support, emergent revascularization
• New murmur (papillary muscle rupture, VSD) — Emergent echocardiography and cardiac surgery consultation
• Complete heart block or Mobitz II (especially anterior MI) — Temporary pacing
• Sustained VT/VF — Defibrillation, antiarrhythmics, consider coronary angiography if post-arrest
• Hypoxemia despite oxygen (SpO2 less than 90% on high-flow O2) — Acute pulmonary edema; may require CPAP or mechanical ventilation
• Persistent chest pain despite reperfusion — Failed reperfusion, recurrent ischemia, mechanical complication

---

5. Differential Diagnosis

Always consider alternative diagnoses, particularly life-threatening conditions that mimic AMI:

Must-Not-Miss Diagnoses

Other Differential Diagnoses

• Myocarditis: Viral prodrome, elevated troponin with normal coronaries on angiography
• GERD/esophageal spasm: Responds to PPI/antacids; relieved by nitroglycerin (confusing!)
• Musculoskeletal pain: Reproducible with palpation; pleuritic component
• Acute cholecystitis: RUQ tenderness, fever, Murphy's sign
• Peptic ulcer disease: Epigastric pain, relationship to food
• Panic attack: Younger patient, hyperventilation, normal ECG and troponin

Clinical Pearl: When in doubt, err on the side of caution—perform ECG and troponin. The consequences of missing AMI far outweigh the costs of over-investigation.

---

6. Investigations

First-Line Investigations (Bedside) — Do Immediately

1. 12-Lead ECG (Within 10 Minutes of Presentation)

Critical Importance: ECG is the single most important initial investigation. It determines whether immediate reperfusion therapy is required. [1,4]

STEMI Criteria (Requires immediate reperfusion):

• ST-elevation ≥1 mm (0.1 mV) in ≥2 contiguous leads, OR
• New left bundle branch block (LBBB) in appropriate clinical context, OR
• Posterior MI: ST-depression V1-V3 with tall R waves (≥ ST-elevation V7-V9)

Contiguous lead groups:

• Anterior: V1-V4 (LAD territory)
• Lateral: I, aVL, V5-V6 (LCx territory)
• Inferior: II, III, aVF (RCA or LCx territory)

NSTEMI/Unstable Angina Findings:

• ST-segment depression ≥0.5 mm
• T-wave inversion ≥1 mm in leads with prominent R waves
• Dynamic ST-T changes (evolving over time)
• Non-diagnostic or normal ECG (in 20-30% of NSTEMIs) [1]

Special ECG Patterns:

• Wellens syndrome: Biphasic or deeply inverted T waves in V2-V4 → critical LAD stenosis
• De Winter pattern: Upsloping ST-depression at J-point + tall symmetric T waves → acute LAD occlusion (STEMI equivalent)
• RV infarction: ST-elevation in V4R (right-sided leads) with inferior STEMI
• Posterior MI: Dominant R wave in V1-V2 + ST-depression → check posterior leads V7-V9

Repeat ECG: Serial ECGs every 15-30 minutes if symptoms persist and initial ECG non-diagnostic.

2. Cardiac Biomarkers: High-Sensitivity Troponin

Troponin: The Gold Standard Biomarker [1,6,7]

Troponin (I or T) is the preferred biomarker for diagnosing AMI. High-sensitivity assays (hs-cTn) detect myocardial injury with exceptional sensitivity, allowing earlier diagnosis but requiring careful interpretation to distinguish MI from other causes of myocardial injury. [6,7]

Fourth Universal Definition of MI (2018): [1] Diagnosis of acute MI requires:

1. Detection of cardiac troponin rise and/or fall, with at least one value > 99th percentile URL, AND
2. At least one of:
   • Symptoms of myocardial ischemia
   • New ischemic ECG changes
   • Development of pathological Q waves
   • Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality
   • Intracoronary thrombus on angiography

Troponin Kinetics: Understanding the Time Course [6,7]

Diagnostic Algorithms Using hs-Troponin: [6,7]

ESC 0/1-Hour Algorithm (High-Sensitivity Troponin):

• Rule-out (very low risk): hs-cTn less than 5 ng/L at presentation AND no significant rise at 1 hour
• Observation zone: hs-cTn between 5-52 ng/L (varies by assay) → repeat at 3 hours
• Rule-in (high probability MI): hs-cTn > 52 ng/L at presentation OR absolute change > 5 ng/L at 1 hour

ESC 0/2-Hour Algorithm:

• Similar concept with longer interval; slightly higher sensitivity, less practical

Troponin Rise/Fall Pattern: [6,7]

• A significant change (≥20% rise or fall OR absolute change > 5-10 ng/L depending on assay) confirms acute MI rather than chronic myocardial injury
• Single elevated value without dynamic change may indicate:
  • Chronic myocardial injury (CKD, heart failure)
  • Type 2 MI (supply-demand mismatch)
  • Myocarditis, takotsubo, PE, sepsis

Non-Ischemic Causes of Troponin Elevation:

• Heart failure (acute or chronic)
• Myocarditis, pericarditis
• Takotsubo cardiomyopathy
• Pulmonary embolism
• Chronic kidney disease
• Sepsis, critical illness
• Cardioversion, ablation
• Cardiac contusion
• Extreme endurance exercise

Clinical Pearl: Troponin elevation indicates myocardial injury, NOT necessarily infarction. Always integrate with clinical context, ECG, and imaging. Serial measurements showing rise/fall pattern are crucial for diagnosis of acute MI. [6,7]

Laboratory Tests

Imaging Investigations

Echocardiography

Indications:

• Suspected mechanical complications (new murmur, shock)
• Assessment of LV function (guide therapy: ACE inhibitor, beta-blocker)
• Uncertain diagnosis (takotsubo, myocarditis)
• Risk stratification (LV ejection fraction less than 40% portends worse prognosis)

Typical Findings:

• Regional wall motion abnormalities (hypokinesis, akinesis, dyskinesis) in coronary territory
• Reduced LVEF (less than 50%)
• Complications: VSD, acute MR (papillary muscle rupture), free wall rupture, LV thrombus, pericardial effusion

Timing: Not required before reperfusion in STEMI (delays treatment); perform once patient stabilized or if complications suspected.

Coronary Angiography

Indications:

• STEMI: Immediate angiography for primary PCI [1,4]
• NSTEMI: Timing based on risk stratification [1,8]
  • "Very high risk (cardiogenic shock, refractory angina, arrhythmia): less than 2 hours"
  • "High risk (GRACE > 140, dynamic ST/T changes, positive troponin): 2-24 hours"
  • "Intermediate risk: 24-72 hours"

Findings:

• Culprit lesion: occlusive or severe stenosis with or without visible thrombus
• Non-culprit disease: multivessel CAD in 40-60% of cases
• TIMI flow grade: 0 (no flow) to 3 (normal flow)

Diagnostic Criteria: The Fourth Universal Definition of MI (2018) [1]

Type 1 MI (Spontaneous plaque rupture/erosion):

• Troponin rise/fall with at least one value > 99th percentile
• Evidence of ischemia (symptoms, ECG, imaging, angiography)

Type 2 MI (Supply-demand mismatch):

• Troponin elevation due to ischemia from causes other than atherothrombosis (e.g., anemia, hypotension, tachyarrhythmia, hypertensive emergency)

Type 3 MI (Sudden cardiac death):

• Cardiac death with presumed new ischemic ECG changes or VF before biomarkers obtained

Type 4a MI (Related to PCI):

• Troponin rise > 5x 99th percentile URL within 48 hours of PCI

Type 5 MI (Related to CABG):

• Troponin rise > 10x 99th percentile URL within 48 hours of CABG

Clinical Utility: Primarily Type 1 MI (spontaneous atherothrombotic) drives acute management. Type 2 MI requires treatment of underlying precipitant.

---

7. Management

Management Algorithm

          SUSPECTED ACUTE MI
    (Chest pain, dyspnea, or ACS-equivalent symptoms)
                    ↓
┌──────────────────────────────────────────────────┐
│      IMMEDIATE ACTIONS (Simultaneous)            │
│  • Call for help, activate ACS protocol          │
│  • 12-lead ECG within 10 minutes                 │
│  • IV access, continuous monitoring              │
│  • Aspirin 300mg PO (chewed)                     │
│  • Oxygen ONLY if SpO2 less than 90%                      │
│  • Analgesia (morphine if severe pain)           │
│  • Bloods: FBC, U&E, troponin, glucose, lipids   │
└──────────────────────────────────────────────────┘
                    ↓
         ECG INTERPRETATION
                    ↓
        ┌───────────┴───────────┐
        ↓                       ↓
   **STEMI**              **Non-STEMI / Unstable Angina**
(ST-elevation ≥1mm         (ST-depression, T-inversion,
in ≥2 contiguous leads)     or normal ECG)
        ↓                       ↓
┌───────────────────┐   ┌─────────────────────┐
│ IMMEDIATE         │   │ RISK STRATIFICATION │
│ REPERFUSION       │   │ (GRACE/TIMI score)  │
│                   │   │                     │
│ Door-to-balloon   │   │ Very High Risk:     │
│ less than 90 minutes       │   │ - Shock, VT/VF      │
│                   │   │ - Refractory angina │
│ PRIMARY PCI       │   │ → Angio less than 2 hours    │
│ (preferred)       │   │                     │
│ OR                │   │ High Risk:          │
│ FIBRINOLYSIS      │   │ - GRACE > 140        │
│ if PCI not        │   │ - Dynamic ST/T Δ    │
│ available         │   │ → Angio 2-24h       │
│ (door-to-needle   │   │                     │
│ less than 30 min)          │   │ Intermediate Risk:  │
└───────────────────┘   │ → Angio 24-72h      │
                        └─────────────────────┘
        ↓                       ↓
┌───────────────────────────────────────────────────┐
│         ADJUNCTIVE PHARMACOTHERAPY                │
│  (All patients unless contraindicated)            │
│                                                   │
│  • DUAL ANTIPLATELET THERAPY:                     │
│    - Aspirin 300mg loading, then 75-100mg daily   │
│    - P2Y12 inhibitor:                             │
│      * Ticagrelor 180mg load, 90mg BD (preferred) │
│      * Prasugrel 60mg load, 10mg daily (if less than 75y)  │
│      * Clopidogrel 600mg load, 75mg daily         │
│                                                   │
│  • ANTICOAGULATION:                               │
│    - Heparin (UFH or LMWH) or bivalirudin         │
│                                                   │
│  • STATIN (high-intensity):                       │
│    - Atorvastatin 80mg daily                      │
│                                                   │
│  • BETA-BLOCKER:                                  │
│    - Start within 24h if no contraindication      │
│      (heart failure, bradycardia, hypotension)    │
│                                                   │
│  • ACE INHIBITOR / ARB:                           │
│    - Start within 24h if LVEF less than 40%, HTN, DM,      │
│      anterior MI                                  │
└───────────────────────────────────────────────────┘
                    ↓
┌───────────────────────────────────────────────────┐
│     MONITORING & COMPLICATION MANAGEMENT          │
│  • Continuous telemetry (48h minimum)             │
│  • Serial troponin, ECG                           │
│  • Echo (assess LV function, complications)       │
│  • Watch for: arrhythmias, heart failure, shock,  │
│    mechanical complications, reinfarction         │
└───────────────────────────────────────────────────┘
                    ↓
┌───────────────────────────────────────────────────┐
│      SECONDARY PREVENTION & REHABILITATION        │
│  • Cardiac rehab referral before discharge        │
│  • Lifestyle: smoking cessation, diet, exercise   │
│  • Risk factor control: BP, lipids, glucose       │
│  • Medications: DAPT (12 months), statin,         │
│    beta-blocker, ACE-I/ARB                        │
│  • Follow-up: 1-2 weeks post-discharge            │
└───────────────────────────────────────────────────┘

Acute Management — The First Hour

Immediate Actions (Do Simultaneously)

1. Activate ACS Protocol

• Call for senior help (cardiology, CCU team)
• Assemble team: physician, nurse, monitor technician
• Prepare for potential reperfusion therapy

2. 12-Lead ECG Within 10 Minutes [1,4]

• Critical for STEMI diagnosis and reperfusion decision
• Do NOT wait for troponin results
• Repeat every 15-30 minutes if symptoms persist and initial ECG non-diagnostic

3. Administer Aspirin Immediately [1,5]

• Dose: 300mg oral (chewed for faster absorption)
• Mechanism: Irreversible COX-1 inhibition → reduced thromboxane A2 → platelet inhibition
• Evidence: Reduces mortality by 20-25% [5]
• Contraindications: Known aspirin allergy (true anaphylaxis rare; consider desensitization if necessary)

4. Oxygen Therapy (Selective Use) [1,4]

• Indication: Hypoxemia (SpO2 less than 90%)
• Dose: Titrate to SpO2 > 90% (not > 95% - hyperoxia may be harmful)
• Evidence: Routine oxygen in normoxemic patients does NOT improve outcomes and may increase infarct size [4]
• Avoid routine oxygen: Only give if indicated

5. Analgesia

• Morphine: 2-5mg IV, repeat every 5-10 minutes as needed for severe pain
  • "Caution: May reduce absorption of oral antiplatelet agents; associated with worse outcomes in some registries"
  • Use judiciously; consider alternatives (fentanyl)
• Nitroglycerin: SL spray or tablets (400-800 mcg) for pain, may improve coronary blood flow
  • "Contraindications: RV infarction, hypotension (SBP less than 90 mmHg), sildenafil use within 24h, tadalafil within 48h"

6. Establish IV Access & Monitoring

• Large-bore IV (for medications, fluids, contrast)
• Continuous cardiac monitoring (detect arrhythmias)

7. Blood Tests

• Troponin (baseline and serial), FBC, U&E, glucose, lipid profile, HbA1c, coagulation screen

---

Reperfusion Therapy for STEMI

Core Principle: Immediate myocardial reperfusion is the single most effective intervention in STEMI. [1,4]

Primary Percutaneous Coronary Intervention (PCI)

Preferred Reperfusion Strategy [1,4]

Target: Door-to-balloon time less than 90 minutes (ideally less than 60 minutes) [4]

Advantages over fibrinolysis:

• Higher patency rates (TIMI 3 flow: 90-95% vs 50-60%)
• Lower mortality (7-9% vs 10-12%)
• Lower risk of intracranial hemorrhage (0.05% vs 1%)
• Lower risk of reinfarction

Indications:

• All STEMI patients presenting within 12 hours of symptom onset
• STEMI with cardiogenic shock (regardless of time from symptom onset)
• Persistent symptoms 12-24 hours after onset if evidence of ongoing ischemia

Procedure:

• Radial access preferred (lower bleeding risk vs femoral)
• Aspiration thrombectomy NOT routinely recommended
• Drug-eluting stent preferred over bare-metal stent
• Multivessel PCI in STEMI controversial: treat culprit lesion; consider staged PCI for non-culprit lesions

Contraindications (relative):

• Patient refusal
• Severe comorbidity limiting life expectancy
• Prolonged CPR with poor neurological prognosis

Fibrinolysis (When PCI Not Available)

Indications: [1,4]

• STEMI presenting within 12 hours of symptom onset
• PCI not available within 120 minutes of first medical contact
• No contraindications to fibrinolysis

Target: Door-to-needle time less than 30 minutes [4]

Fibrinolytic Agents:

Absolute Contraindications:

• Any prior intracranial hemorrhage
• Known structural cerebrovascular lesion (AVM, aneurysm)
• Ischemic stroke within 3 months (except within 4.5 hours)
• Active bleeding or bleeding diathesis
• Suspected aortic dissection
• Closed head/facial trauma within 3 months

Relative Contraindications:

• Uncontrolled hypertension (SBP > 180 mmHg, DBP > 110 mmHg)
• Current use of anticoagulation (INR > 2-3)
• Recent internal bleeding (2-4 weeks)
• Pregnancy
• Active peptic ulcer
• Recent major surgery (less than 3 weeks)

Post-Fibrinolysis Management:

• Assess reperfusion success at 60-90 minutes: ≥50% ST-segment resolution = successful reperfusion [4]
• Failed reperfusion (persistent ST-elevation, ongoing pain): rescue PCI
• Routine angiography 3-24 hours post-fibrinolysis (even if successful reperfusion)

---

Pharmacotherapy: Dual Antiplatelet Therapy (DAPT)

DAPT = Aspirin + P2Y12 Inhibitor [5,9,10]

Aspirin (Irreversible COX-1 inhibitor):

• Loading dose: 300mg PO (chewed)
• Maintenance: 75-100mg daily indefinitely
• Evidence: 20-25% mortality reduction [5]

P2Y12 Inhibitors (ADP receptor antagonists):

Choice of P2Y12 Inhibitor: [9,10]

• First-line: Ticagrelor or prasugrel (superior efficacy vs clopidogrel)
• Prasugrel contraindicated if: Age > 75y, weight less than 60kg, prior stroke/TIA
• Clopidogrel if: Contraindication to ticagrelor/prasugrel, high bleeding risk, elderly (> 75y)

Duration of DAPT: [9,10]

• Standard duration: 12 months post-ACS (Class I recommendation)
• Consider shorter duration (3-6 months): High bleeding risk (HAS-BLED ≥3)
• Consider longer duration (> 12 months): High ischemic risk, low bleeding risk, patient preference
• After 12 months: Continue aspirin indefinitely; stop P2Y12 inhibitor unless compelling indication

DAPT Trials: STOPDAPT-2 ACS trial showed non-inferiority of 1-2 months DAPT followed by clopidogrel monotherapy vs 12 months DAPT in selected ACS patients, challenging traditional duration. [10]

Anticoagulation

Indications: All ACS patients undergoing PCI or receiving fibrinolysis [1]

Options:

Duration: Usually discontinued after PCI or after fibrinolysis period; longer duration if specific indication (e.g., LV thrombus, AF).

Statin Therapy

Recommendation: High-intensity statin for ALL ACS patients [1,5]

• Agent: Atorvastatin 80mg daily (most evidence) or rosuvastatin 20-40mg daily
• Timing: Start immediately (within 24 hours of admission)
• Mechanism: Plaque stabilization, anti-inflammatory effects, improved endothelial function
• Evidence: Reduces recurrent MI, stroke, and mortality by 20-30% [5]
• Target: LDL less than 1.8 mmol/L (70 mg/dL); even lower (less than 1.4 mmol/L) in very high-risk patients

Beta-Blockers

Recommendation: Initiate within 24 hours if no contraindications [1,5]

Benefits:

• Reduce myocardial oxygen demand (↓ HR, ↓ contractility, ↓ BP)
• Reduce arrhythmia risk
• Improve long-term survival (especially if LVEF less than 40%)

Contraindications:

• Cardiogenic shock or risk of shock
• Decompensated heart failure (start after stabilization and diuresis)
• Heart block (2nd/3rd degree), symptomatic bradycardia (HR less than 60)
• Severe reactive airway disease

Agents and Dosing:

• Metoprolol: 25-50mg PO BD, titrate to 100mg BD
• Bisoprolol: 2.5mg daily, titrate to 10mg daily
• Carvedilol: 3.125mg BD, titrate to 25mg BD

ACE Inhibitors / ARBs

Recommendation: Start within 24 hours in patients with: [1,5]

• Anterior MI
• LVEF less than 40%
• Heart failure
• Diabetes mellitus
• Hypertension

Benefits:

• Reduce adverse LV remodeling
• Reduce mortality (10-20% relative risk reduction)
• Reduce heart failure hospitalization

Contraindications:

• Hypotension (SBP less than 90-100 mmHg)
• Bilateral renal artery stenosis
• Pregnancy
• Hyperkalemia (K+ > 5.5 mmol/L)
• Severe renal impairment (use with caution, monitor K+ and creatinine)

Agents:

• Ramipril: Start 2.5mg daily, titrate to 10mg daily
• Enalapril: Start 2.5mg BD, titrate to 10mg BD
• ARBs (if ACE-I intolerant): Valsartan 40mg BD, titrate to 160mg BD

Aldosterone Antagonists

Indication: LVEF ≤40% AND heart failure or diabetes mellitus (in addition to ACE-I and beta-blocker) [5]

• Eplerenone: 25mg daily, titrate to 50mg daily (preferred; fewer side effects)
• Spironolactone: 25mg daily (gynecomastia, hyperkalemia risk)
• Evidence: 15% mortality reduction in EPHESUS trial [5]
• Monitoring: Check K+ and creatinine at 1 week, then monthly

---

Risk Stratification Post-MI

Purpose: Identify high-risk patients requiring more aggressive therapy or early invasive management [8]

GRACE Score (Global Registry of Acute Coronary Events) [8]

Components (8 variables):

1. Age
2. Heart rate
3. Systolic BP
4. Creatinine
5. Cardiac arrest at admission
6. ST-segment deviation
7. Elevated cardiac biomarkers
8. Killip class (heart failure severity)

Risk Categories:

• Low risk (less than 108): less than 1% in-hospital mortality, less than 3% 6-month mortality → angiography 24-72h
• Intermediate risk (109-140): 1-3% in-hospital mortality, 3-8% 6-month mortality → angiography within 24h
• High risk (> 140): > 3% in-hospital mortality, > 8% 6-month mortality → angiography within 2-24h

Clinical Use: GRACE score is preferred in NSTEMI for risk stratification and timing of angiography [1,8]

TIMI Risk Score (Thrombolysis in Myocardial Infarction) [8]

Simpler score (7 variables, 0-7 points):

• Age ≥65 years
• ≥3 CAD risk factors
• Known CAD (stenosis ≥50%)
• Aspirin use in prior 7 days
• Severe angina (≥2 episodes in 24h)
• ST-deviation ≥0.5mm
• Elevated cardiac markers

Risk: 0-2 points = low risk (5% event rate); 5-7 points = high risk (40% event rate)

Killip Classification (Heart Failure Severity)

---

Disposition and Monitoring

Admission:

• All AMI patients require hospital admission
• CCU/ICU: STEMI, cardiogenic shock, arrhythmias, mechanical complications
• Monitored bed: NSTEMI, stable post-PCI

Monitoring:

• Continuous telemetry for ≥24-48 hours (arrhythmia detection)
• Serial ECGs (evolving changes, reinfarction)
• Serial troponin (peak level correlates with infarct size)
• Daily clinical assessment (symptoms, vital signs, fluid balance)

Length of Stay:

• Uncomplicated STEMI post-PCI: 2-3 days
• Uncomplicated NSTEMI: 3-5 days
• Complicated MI: Variable (depends on complications)

Discharge Criteria:

• Hemodynamically stable for ≥24 hours
• No recurrent ischemia
• No high-grade arrhythmias
• Heart failure controlled (if present)
• Ambulating without symptoms
• Medications optimized
• Cardiac rehabilitation arranged
• Follow-up scheduled

---

8. Complications

Immediate Complications (Hours to Days)

1. Arrhythmias (Most Common Complication)

VF Risk Factors: Anterior MI, delayed reperfusion, electrolyte abnormalities (K+ less than 4.0, Mg2+ less than 2.0), ongoing ischemia

2. Heart Failure and Cardiogenic Shock

Acute Heart Failure (20-30% of STEMI): [11]

• Mechanism: LV dysfunction from myocardial necrosis, stunning
• Clinical: Dyspnea, crackles, elevated JVP, S3 gallop
• Management: Diuretics (furosemide), ACE inhibitors (once stable), beta-blockers (once compensated), aldosterone antagonists if LVEF less than 40%

Cardiogenic Shock (5-7% of STEMI): [11]

• Definition: SBP less than 90 mmHg for > 30 min with signs of hypoperfusion (cold extremities, altered mentation, oliguria less than 0.5 mL/kg/h, lactate > 2 mmol/L)
• Mortality: 40-50% despite revascularization
• Management:
  • Emergent revascularization (PCI or CABG) - improves survival
  • "Inotropes: Dobutamine (2.5-20 mcg/kg/min) or dopamine (5-20 mcg/kg/min)"
  • "Mechanical circulatory support: Intra-aortic balloon pump (IABP), Impella, VA-ECMO"
  • Avoid beta-blockers and ACE inhibitors until stabilized

3. Mechanical Complications (Rare but Catastrophic) [12]

Red Flag: New murmur + hemodynamic deterioration = mechanical complication until proven otherwise. Urgent echocardiography and cardiac surgery consultation mandatory. [12]

4. Pericarditis

• Early pericarditis (1-4 days, 5-10%): Inflammation of pericardium overlying infarct; pleuritic chest pain, friction rub; treat with aspirin/NSAIDs (avoid in first 48h post-MI)
• Dressler syndrome (weeks to months, less than 1%): Autoimmune pericarditis; fever, pericardial effusion, pleuritis; treat with NSAIDs or colchicine

Late Complications (Weeks to Months)

1. Chronic Heart Failure (20-30% of Post-MI Patients) [11]

• Mechanism: Extensive myocardial necrosis (> 20-30% of LV), adverse ventricular remodeling
• Prevention: Early reperfusion, ACE inhibitors, beta-blockers, aldosterone antagonists, optimal medical therapy
• Management: Guideline-directed medical therapy (GDMT), ICD if LVEF ≤35% > 40 days post-MI, CRT if indicated

2. Recurrent Ischemia / Reinfarction (5-10%)

• Mechanism: Re-occlusion of culprit vessel, progression of non-culprit disease, stent thrombosis
• Prevention: DAPT adherence, optimal medical therapy, risk factor modification
• Management: Urgent angiography

3. Sudden Cardiac Death (Post-Discharge)

• Risk factors: LVEF less than 35%, non-sustained VT, inducible VT on EP study
• Prevention: ICD implantation if LVEF ≤35% at ≥40 days post-MI (and ≥90 days post-revascularization)

---

9. Prognosis & Outcomes

Natural History (Without Treatment)

Historical Mortality (Pre-Reperfusion Era):

• In-hospital mortality: 20-30%
• 1-year mortality: 30-40%

Modern Outcomes (With Contemporary Therapy)

Short-Term Mortality: [2,4]

• STEMI: 5-7% in-hospital mortality (with primary PCI); 10-12% (with fibrinolysis)
• NSTEMI: 3-5% in-hospital mortality
• 30-day mortality: 8-10% overall

Long-Term Outcomes: [5]

• 1-year mortality: 10-12% (STEMI), 8-10% (NSTEMI)
• 5-year mortality: 20-25%
• Recurrent MI: 10% at 1 year, 20-30% at 5 years
• Heart failure: 20-30% develop chronic HF

Prognostic Factors

Factors Associated with Poor Prognosis:

Factors Associated with Good Prognosis:

• Early reperfusion (less than 90 min door-to-balloon for STEMI) [4]
• Complete revascularization
• Preserved LVEF (> 50%)
• No complications
• Young age, no comorbidities
• Adherence to guideline-directed medical therapy and secondary prevention [5]

---

10. Secondary Prevention & Long-Term Management

Goal: Prevent recurrent events, optimize quality of life, and prolong survival. [5,9]

Pharmacological Secondary Prevention (ABCDE Mnemonic)

A - Antiplatelet Therapy [5,9,10]

• DAPT for 12 months: Aspirin 75-100mg daily + P2Y12 inhibitor (ticagrelor 90mg BD, prasugrel 10mg daily, or clopidogrel 75mg daily)
  • Reduces recurrent MI, stent thrombosis, CV death
• After 12 months: Aspirin 75-100mg daily indefinitely (unless high bleeding risk)

B - Beta-Blocker [5]

• Continue indefinitely, especially if LVEF less than 40% or heart failure
• Reduces arrhythmia, recurrent MI, mortality (30% relative risk reduction in LVEF less than 40%)
• Target: Resting HR 55-60 bpm

C - Cholesterol (Statin) [5]

• High-intensity statin: Atorvastatin 80mg daily or rosuvastatin 20-40mg daily
• Target: LDL less than 1.8 mmol/L (70 mg/dL), ideally less than 1.4 mmol/L (55 mg/dL)
• Consider ezetimibe if target not achieved
• Consider PCSK9 inhibitors (evolocumab, alirocumab) if LDL remains elevated despite statin + ezetimibe

D - Diet, Diabetes, and Blood Pressure Control

• Diet: Mediterranean diet, reduce saturated fats, increase fiber, omega-3 fatty acids
• Diabetes: Target HbA1c less than 7% (strict control); SGLT2 inhibitors and GLP-1 agonists reduce CV events
• Blood pressure: Target less than 130/80 mmHg; ACE inhibitor or ARB preferred

E - Exercise and ACE Inhibitor/ARB [5]

• ACE inhibitor/ARB: Continue indefinitely if LVEF less than 40%, heart failure, hypertension, or diabetes
• Exercise: Cardiac rehabilitation (supervised exercise program, risk factor education)
  • Reduces mortality by 20-30%, improves quality of life [13]
  • "Target: 150 min/week moderate-intensity aerobic exercise"

Lifestyle Modifications [5,13]

Cardiac Rehabilitation [13,14]

Components:

1. Exercise training: Supervised progressive exercise program
2. Risk factor modification: Smoking cessation, diet, weight management
3. Education: Disease understanding, medication adherence, symptom recognition
4. Psychosocial support: Depression screening, counseling

Evidence: Cochrane review of 63 RCTs (14,486 patients) shows cardiac rehabilitation reduces: [13]

• CV mortality by 26%
• Hospital admissions by 18%
• Improves quality of life

Enrollment: All post-MI patients should be referred before discharge; early initiation (within 1-3 weeks) optimal [13,14]

Follow-Up Schedule

• 1-2 weeks post-discharge: GP or cardiology review
  • Assess symptoms, medication adherence, side effects
  • Check BP, HR, signs of heart failure
  • "Blood tests: U&E (if on ACE-I/ARB), lipids (check statin response)"
• 4-6 weeks: Echocardiography to reassess LVEF (guide ICD consideration if LVEF ≤35%)
• 3 months: Cardiology review
• 6-12 months: Annual review thereafter
• Long-term: Lifelong follow-up with GP; cardiology as needed

Implantable Cardioverter-Defibrillator (ICD)

Indication: LVEF ≤35% at ≥40 days post-MI (and ≥90 days post-revascularization) despite optimal medical therapy [5]

• Evidence: Reduces sudden cardiac death by 50-60% (SCD-HeFT, MADIT-II trials)
• Reassess LVEF at 4-6 weeks and 3 months post-MI before ICD decision

---

11. Evidence & Guidelines

Key Guidelines

1. ESC Guidelines for STEMI (2017) — Ibanez B, et al. [4]

Key Recommendations (Class I, Level A):

• Primary PCI preferred over fibrinolysis (door-to-balloon less than 90 min)
• 12-lead ECG within 10 minutes of presentation
• DAPT: Aspirin + ticagrelor or prasugrel (or clopidogrel if contraindications)
• High-intensity statin initiated immediately
• ACE inhibitor/ARB in all patients with LVEF less than 40%, heart failure, diabetes, or anterior MI
• Beta-blocker in all patients without contraindications

2. Fourth Universal Definition of Myocardial Infarction (2018) — Thygesen K, et al. [1]

Key Concepts:

• AMI defined by troponin rise/fall with clinical evidence of myocardial ischemia
• Five types of MI based on etiology (Type 1: spontaneous plaque rupture)
• High-sensitivity troponin enables earlier diagnosis but requires serial testing and clinical correlation

3. ACC/AHA Guidelines for DAPT (2016) — Levine GN, et al. [9]

Key Recommendations:

• DAPT (aspirin + P2Y12 inhibitor) for 12 months post-ACS (Class I)
• Ticagrelor or prasugrel preferred over clopidogrel (Class I)
• Shorter DAPT duration (3-6 months) reasonable in high bleeding risk (Class IIb)

Landmark Trials

Reperfusion Trials:

• DANAMI-2 (2003): Primary PCI superior to fibrinolysis (30-day mortality: 6.6% vs 7.8%)
• TRANSFER-AMI (2011): Routine early PCI after fibrinolysis improves outcomes vs ischemia-guided strategy [8]

Antiplatelet Trials:

• PLATO (2009): Ticagrelor superior to clopidogrel in ACS (9.8% vs 11.7% CV death/MI/stroke at 12 months) [9,10]
• TRITON-TIMI 38 (2007): Prasugrel superior to clopidogrel in ACS undergoing PCI (9.9% vs 12.1% events) [9,10]
• STOPDAPT-2 ACS (2022): 1-2 months DAPT followed by clopidogrel monotherapy non-inferior to 12 months DAPT in selected ACS patients [10]

Secondary Prevention Trials:

• 4S, HPS, PROVE-IT: High-intensity statins reduce recurrent events and mortality by 25-30% [5]
• HOPE, EUROPA: ACE inhibitors reduce recurrent MI, stroke, CV death by 20-25% [5]
• Cochrane Review (2021): Cardiac rehabilitation reduces CV mortality by 26% and hospitalizations by 18% [13]

Evidence Strength Summary

---

11. Exam-Focused Content

Common Exam Questions

Question 1: "How do you differentiate STEMI from NSTEMI?"

Model Answer:

"The key distinction between STEMI and NSTEMI lies in the ECG findings and the underlying pathophysiology. [1,4]

STEMI (ST-Elevation Myocardial Infarction):

• ECG: ST-segment elevation ≥1 mm in at least 2 contiguous leads, OR new left bundle branch block in appropriate clinical context
• Pathophysiology: Complete, persistent occlusion of a coronary artery (> 90% of cases)
• Myocardial territory: Transmural (full-thickness) ischemia
• Management: Immediate reperfusion therapy mandatory (primary PCI within 90 minutes or fibrinolysis within 30 minutes)
• Early mortality: 5-7% with modern treatment

NSTEMI (Non-ST-Elevation Myocardial Infarction):

• ECG: ST-segment depression, T-wave inversion, or even normal ECG in 20-30% of cases
• Pathophysiology: Partial occlusion, intermittent occlusion, or complete occlusion with collateral flow
• Myocardial territory: Subendocardial (inner layer) ischemia
• Management: Risk stratification (GRACE score) determines timing of angiography (very high risk: less than 2h; high risk: 2-24h; intermediate: 24-72h)
• Early mortality: 3-5% but long-term outcomes similar to STEMI if high-risk features present

Both conditions require elevated cardiac troponin with a rise/fall pattern characteristic of acute myocardial injury. The key clinical implication is that STEMI requires immediate reperfusion, whereas NSTEMI requires urgent but not necessarily immediate intervention, with timing determined by risk stratification. [1,4]"

---

Question 2: "Explain troponin kinetics in acute MI and how you use them diagnostically"

Model Answer:

"Troponin is the preferred biomarker for diagnosing acute myocardial infarction, but understanding its kinetics is crucial for accurate interpretation. [6,7]

Temporal Profile:

• Onset of elevation: Conventional troponin rises at 3-4 hours; high-sensitivity troponin (hs-cTn) rises as early as 1-3 hours post-symptom onset
• Peak level: 12-24 hours (magnitude correlates with infarct size)
• Return to baseline: 7-14 days (prolonged elevation limits detection of reinfarction)

Diagnostic Criteria (Fourth Universal Definition of MI, 2018): [1]

• Cardiac troponin value exceeding the 99th percentile upper reference limit (URL), AND
• Dynamic rise (≥20% change) or fall pattern confirming acute injury

High-Sensitivity Troponin Algorithms: [6,7,29]

ESC 0/1-Hour Algorithm:

• Rule-out (very low probability MI): hs-cTn less than 5 ng/L at presentation AND no significant rise at 1 hour → discharge with safety netting
• Observation zone: hs-cTn 5-52 ng/L (varies by assay) → repeat at 3 hours
• Rule-in (high probability MI): hs-cTn > 52 ng/L at presentation OR absolute change > 5 ng/L at 1 hour → proceed with ACS management

Critical Distinction - Myocardial Injury vs Infarction: [6,7]

• Single elevated troponin = myocardial injury (NOT necessarily infarction)
• Rise/fall pattern = acute MI (confirms acute event)

Non-Ischemic Causes of Troponin Elevation:

• Chronic kidney disease (most common)
• Heart failure (acute or chronic)
• Myocarditis, takotsubo cardiomyopathy
• Pulmonary embolism
• Sepsis, critical illness
• Extreme endurance exercise

Clinical Integration: Always interpret troponin in clinical context with:

1. Clinical presentation (chest pain characteristics)
2. ECG findings (ST-segment changes, T-wave abnormalities)
3. Imaging (echocardiography showing regional wall motion abnormalities)
4. Serial measurements (demonstrating dynamic change)

High-sensitivity assays have increased diagnostic sensitivity (allowing earlier rule-in) but reduced specificity (more false positives). Therefore, serial troponin measurements and clinical correlation are mandatory to differentiate Type 1 MI (acute plaque rupture) from Type 2 MI (supply-demand mismatch) and non-ischemic myocardial injury. [1,6,7]"

---

Question 3: "What are the time-critical targets for STEMI management and why do they matter?"

Model Answer:

"Time-critical reperfusion is the cornerstone of STEMI management. The mantra 'time is muscle' reflects the exponential relationship between treatment delay and mortality. [4,20]

Key Time Targets: [4]

1. ECG acquisition: less than 10 minutes from first medical contact

   • Why: ECG is the decision-making tool for immediate reperfusion
   • Delays in ECG = delays in diagnosis = delays in treatment

2. Door-to-balloon time: less than 90 minutes (ideally less than 60 minutes)

   • Definition: Time from hospital arrival to first balloon inflation during primary PCI
   • Why: Every 30-minute delay increases 1-year mortality by 7.5% [4,20]
   • Best outcomes: less than 60 minutes (5-6% mortality) vs > 90 minutes (10-12% mortality)

3. Door-to-needle time: less than 30 minutes (if fibrinolysis chosen)

   • Definition: Time from hospital arrival to fibrinolytic bolus
   • Why: Fibrinolysis is time-sensitive; efficacy decreases exponentially after 3 hours
   • Optimal: Within 2-3 hours of symptom onset (greatest mortality benefit)

4. First medical contact to reperfusion: less than 120 minutes

   • Total ischemic time from calling ambulance to reperfusion
   • Critical for patients presenting to non-PCI centers requiring transfer

Why Time Matters - The Pathophysiology: [1,3]

• Myocardial necrosis begins 20-30 minutes after complete coronary occlusion
• "Wavefront phenomenon": Necrosis progresses from subendocardium to subepicardium over 3-6 hours
• Salvageable myocardium decreases exponentially with time
• Early reperfusion (less than 2 hours) can salvage 50-70% of ischemic myocardium
• Delayed reperfusion (> 6 hours) salvages less than 20%

Clinical Outcomes: [4]

• less than 60 min door-to-balloon: 4-5% mortality
• 60-90 min: 5-7% mortality
• 90-120 min: 8-10% mortality
• > 120 min: 12-15% mortality

System of Care Implications:

• Pre-hospital ECG acquisition (paramedics)
• Direct transfer to cath lab (bypass emergency department)
• Cath lab activation while patient en route
• 24/7 primary PCI capability
• If PCI not available within 120 minutes: Fibrinolysis at presenting hospital followed by transfer for angiography

Every healthcare system should track door-to-balloon times as a key performance indicator. Delays are often system-based (not clinical), and quality improvement initiatives targeting time metrics save lives. [4,20]"

---

Question 4: "Describe your approach to dual antiplatelet therapy in acute MI"

Model Answer:

"Dual antiplatelet therapy (DAPT) is a cornerstone of acute MI management, reducing recurrent ischemic events and stent thrombosis. [5,9,10]

Definition: Aspirin PLUS a P2Y12 inhibitor (ticagrelor, prasugrel, or clopidogrel)

Loading Doses (given immediately upon ACS diagnosis): [1,9]

• Aspirin: 300mg PO (chewed for rapid absorption)
• PLUS one of:
  • "Ticagrelor: 180mg PO (preferred in most ACS patients)"
  • "Prasugrel: 60mg PO (preferred if undergoing PCI, age less than 75y, no prior stroke)"
  • "Clopidogrel: 600mg PO (if contraindications to ticagrelor/prasugrel)"

Maintenance Therapy:

• Aspirin: 75-100mg daily (indefinitely)
• PLUS:
  • "Ticagrelor: 90mg BD"
  • "Prasugrel: 10mg daily (5mg if weight less than 60kg)"
  • "Clopidogrel: 75mg daily"

Choice of P2Y12 Inhibitor: [9,10]

First-Line: Ticagrelor or Prasugrel (superior to clopidogrel)

• PLATO trial (ticagrelor): 9.8% vs 11.7% CV death/MI/stroke at 12 months (16% relative risk reduction) [9]
• TRITON-TIMI 38 (prasugrel): 9.9% vs 12.1% events (19% relative risk reduction) [9]

Prasugrel contraindications:

• Age > 75 years
• Weight less than 60kg
• Prior stroke or TIA
• (Higher bleeding risk outweighs ischemic benefit)

Use Clopidogrel if:

• Age > 75 years (POPular AGE trial showed non-inferiority of clopidogrel in elderly) [16]
• High bleeding risk (HAS-BLED score ≥3)
• Contraindication/intolerance to ticagrelor or prasugrel
• Cost considerations

Duration of DAPT: [9,10]

Standard: 12 months post-ACS (Class I recommendation)

• Balance ischemic protection vs bleeding risk
• Greatest ischemic benefit in first 12 months

Consider Shorter Duration (3-6 months):

• High bleeding risk (HAS-BLED ≥3, prior major bleeding, elderly/frail)
• STOPDAPT-2 ACS trial: 1-2 months DAPT followed by clopidogrel monotherapy non-inferior to 12 months DAPT in selected patients [10]

Consider Longer Duration (> 12 months):

• High ischemic risk (multivessel disease, diabetes, recurrent ACS, complex PCI)
• Low bleeding risk
• Patient preference after informed discussion

After 12 Months:

• Continue aspirin indefinitely (lifelong secondary prevention)
• Discontinue P2Y12 inhibitor (unless specific indication like recurrent ACS)

Common Pitfalls:

1. Premature discontinuation: Leading cause of stent thrombosis (catastrophic outcome)
2. Inadequate loading: Morphine delays absorption of oral antiplatelet agents
3. Clopidogrel non-responders: 25-30% have CYP2C19 polymorphism reducing efficacy (consider ticagrelor/prasugrel)
4. Failure to address bleeding risk: Proton pump inhibitor recommended if high GI bleeding risk

Monitoring: No routine platelet function testing recommended (except in specific situations like clopidogrel non-response concern)

DAPT adherence is critical - educate patients about:

• Importance of NOT stopping medications without cardiology consultation
• Signs of bleeding (report immediately)
• Stent thrombosis risk if stopped early (> 50% mortality) [9,10,17]"

---

Question 5: "How do you risk-stratify patients with NSTEMI and what does this guide?"

Model Answer:

"Risk stratification in NSTEMI is essential to determine the timing and intensity of invasive and medical therapy. Unlike STEMI, NSTEMI does not mandate immediate angiography - timing depends on ischemic risk vs bleeding risk. [1,8]

Risk Stratification Tools:

1. GRACE Score (Global Registry of Acute Coronary Events) - Preferred [8,25,26]

Variables (8 components):

• Age (higher = worse)
• Heart rate (higher = worse)
• Systolic blood pressure (lower = worse)
• Serum creatinine (higher = worse)
• Cardiac arrest at admission (yes = worse)
• ST-segment deviation on ECG (yes = worse)
• Elevated cardiac biomarkers (yes = worse)
• Killip class (heart failure severity: I-IV)

Interpretation: [8,25,26]

• Low risk: less than 108 points
  • In-hospital mortality less than 1%, 6-month mortality less than 3%
  • "Timing of angiography: 24-72 hours (elective, next available slot)"
• Intermediate risk: 109-140 points
  • In-hospital mortality 1-3%, 6-month mortality 3-8%
  • "Timing: Within 24 hours"
• High risk: > 140 points
  • In-hospital mortality > 3%, 6-month mortality > 8%
  • "Timing: 2-24 hours (urgent)"

GRACE Score Advantages:

• Validated across multiple international cohorts
• Continuous score (not just categorical)
• Accounts for both ischemic events AND mortality
• Guides timing of invasive strategy per ESC guidelines

2. TIMI Risk Score (Thrombolysis in Myocardial Infarction) [27,28]

Variables (7 components, 1 point each):

• Age ≥65 years
• ≥3 cardiovascular risk factors (HTN, DM, smoking, FH, hyperlipidemia)
• Known CAD (≥50% stenosis on prior angiography)
• Aspirin use in past 7 days
• ≥2 anginal episodes in 24 hours
• ST-segment deviation ≥0.5mm on ECG
• Elevated cardiac markers

Score Interpretation: [27,28]

• 0-2 points: Low risk (5% event rate at 14 days)
• 3-4 points: Intermediate risk (13% event rate)
• 5-7 points: High risk (26-41% event rate)

TIMI Advantages:

• Simple bedside calculation
• No laboratory values required (except troponin)
• Validated for short-term risk prediction

Very High-Risk Features (Immediate angiography less than 2 hours): [1,31]

• Cardiogenic shock or hemodynamic instability
• Recurrent or refractory angina despite medical therapy
• Life-threatening arrhythmias (VT, VF)
• Mechanical complications (acute MR, VSD)
• Acute heart failure (Killip Class III-IV)
• Recurrent dynamic ST-T wave changes (especially ST-elevation)

Timing of Invasive Strategy Based on Risk: [1,31]

Clinical Application:

Example 1: 55-year-old male, NSTEMI, GRACE score 95 (low risk), hemodynamically stable, chest pain resolved on medical therapy

• Plan: Optimal medical therapy (DAPT, statin, beta-blocker, ACE-I), angiography within 72 hours (next available elective slot), consider early discharge if pain-free

Example 2: 72-year-old female, NSTEMI, GRACE score 155 (high risk), ongoing chest pain despite nitrates, dynamic ST-depression, troponin 5000 ng/L

• Plan: Urgent angiography within 2-12 hours, intensive medical therapy, plan for likely PCI

Example 3: 65-year-old male, NSTEMI, develops cardiogenic shock 4 hours after admission

• Plan: Immediate angiography (less than 2 hours), likely multivessel disease or mechanical complication, consider mechanical circulatory support

Balancing Ischemic vs Bleeding Risk:

• High GRACE score + high bleeding risk (HAS-BLED ≥3): Still pursue invasive strategy but use radial access, minimize contrast, shorter DAPT duration, PPI for GI protection
• Very elderly/frail with multiple comorbidities: Multidisciplinary discussion; conservative management may be appropriate if quality of life concerns

Risk stratification is NOT just about timing - it also guides:

• Intensity of antiplatelet therapy (potent P2Y12 inhibitor in high-risk)
• Need for GPIIb/IIIa inhibitors (rarely used now)
• Post-discharge follow-up intensity
• Patient prognostication and counseling [8,25-28,31]"

---

Viva Scenarios

Scenario 1: STEMI with Cardiogenic Shock

Examiner: "A 58-year-old man presents with 2 hours of central chest pain. His BP is 85/60 mmHg, HR 110 bpm, cold and clammy. ECG shows anterior STEMI. How do you manage this patient?"

Model Answer:

"This patient has STEMI complicated by cardiogenic shock - a life-threatening emergency requiring immediate, multifaceted intervention. [4,11]

Immediate Assessment (ABCDE):

• Airway: Likely patent but assess; prepare for intubation if deteriorating
• Breathing: High-flow oxygen if hypoxemic (SpO2 less than 90%); assess for pulmonary edema
• Circulation: Cardiogenic shock confirmed (SBP less than 90 mmHg + hypoperfusion signs)
• Disability: Assess consciousness (shock may cause confusion)
• Exposure: Full exam for mechanical complications

Immediate Management (Parallel interventions):

1. Activate Cath Lab Immediately [4,11]

   • Cardiogenic shock is an indication for emergent PCI (within 60 minutes if possible)
   • This is the ONLY intervention proven to reduce mortality in cardiogenic shock
   • Transfer to cath lab BEFORE stabilization attempts (don't delay for Swan-Ganz catheter, echo, etc.)

2. Hemodynamic Support (en route to cath lab): [11]

   • IV fluid challenge: 250-500mL crystalloid rapidly (assess response; avoid if pulmonary edema present)
   • Inotrope: Dobutamine 2.5-10 mcg/kg/min (preferred; improves contractility and reduces afterload)
     • OR Dopamine 5-15 mcg/kg/min (alternative; increases BP but also increases afterload)
   • Avoid beta-blockers, ACE inhibitors, nitrates (all worsen hypotension)

3. Antiplatelet and Anticoagulation: [9]

   • Aspirin 300mg PO/IV
   • P2Y12 inhibitor: Ticagrelor 180mg PO or prasugrel 60mg PO (if able to swallow)
     • If unable to take PO: Give via NG tube or consider IV cangrelor in cath lab
   • Anticoagulation: Unfractionated heparin 70-100 U/kg IV bolus

4. Prepare for Mechanical Circulatory Support: [11]

   • Alert team to potential need for:
     • Intra-aortic balloon pump (IABP): Counterpulsation increases coronary perfusion, reduces afterload
     • Impella: Percutaneous LV assist device (more powerful than IABP)
     • VA-ECMO: For refractory shock

In the Cath Lab: [11]

• Identify and treat culprit lesion (likely LAD given anterior STEMI and shock)
• Assess for multivessel disease (common in cardiogenic shock)
• Culprit-only PCI in shock (treat culprit first; staged PCI for non-culprit lesions later if needed)
• Consider mechanical support if unable to wean inotropes

Post-PCI Care (CCU):

• Invasive monitoring: Arterial line, consider PA catheter
• Serial lactate, urine output, mental status (assess end-organ perfusion)
• Echocardiography: Assess LV function (LVEF likely less than 30-35%), mechanical complications (VSR, acute MR, free wall rupture)
• Gradual wean of inotropes as hemodynamics improve

Prognosis and Counseling:

• Cardiogenic shock complicates 5-7% of STEMIs
• Mortality 40-50% despite revascularization
• Early revascularization (within 6-12 hours) reduces mortality by 30-40%
• Survivors often have significant LV dysfunction requiring long-term HF therapy and consideration for ICD

What NOT to Do:

• ❌ Delay cath lab for stabilization (revascularization IS the stabilization)
• ❌ Give beta-blockers (worsens shock)
• ❌ Aggressive fluid resuscitation if pulmonary edema present
• ❌ Treat non-culprit lesions during index procedure (increases procedural time/contrast/complications) [4,11]"

---

Scenario 2: Inferior STEMI with Bradycardia and Hypotension

Examiner: "60-year-old woman with inferior STEMI. HR 45 bpm, BP 90/55 mmHg. She feels dizzy. What's your approach?"

Model Answer:

"This presentation suggests inferior STEMI with likely RV involvement causing bradycardia and hypotension - a specific management challenge. [1,4]

Key Considerations:

• Inferior STEMI (RCA or LCx occlusion) commonly causes bradycardia and AV block due to:
  • RCA supplies SA node (60%) and AV node (90%)
  • Vagal activation (Bezold-Jarisch reflex)
• RV infarction occurs in 30-50% of inferior STEMIs
• RV dysfunction causes reduced LV preload → hypotension
• Critical: Treatment differs from LV-predominant STEMI

Immediate Assessment:

1. Confirm RV Involvement: [4]

   • Right-sided ECG: Place V4R lead (ST-elevation in V4R confirms RV infarction)
   • Standard ECG clues: Inferior ST-elevation + ST-elevation V1 (suggests RV)

2. Assess Hemodynamic Impact:

   • Symptomatic bradycardia (dizziness, presyncope, hypotension)
   • Signs of RV failure: Elevated JVP, clear lung fields (absence of pulmonary edema), hypotension
   • Kussmaul sign (JVP rises with inspiration)

Management:

1. Treat Bradycardia: [4]

• Atropine 0.5-1mg IV (repeat up to 3mg total)
  • Usually effective for sinus bradycardia and AV nodal block in inferior MI
  • Reverses vagal tone
• If atropine fails: Temporary transvenous pacing
  • "Indications: Symptomatic bradycardia unresponsive to atropine, high-grade AV block"

2. RV Infarction-Specific Management: [4]

• Aggressive IV fluid resuscitation: 500-1000mL crystalloid rapidly
  • RV dysfunction requires high filling pressures
  • Monitor response (BP, urine output, JVP)
  • Continue until BP stabilizes or signs of pulmonary edema develop
• Maintain AV synchrony: Avoid junctional rhythms (pace in DDD mode if needed)
• AVOID:
  • ❌ Nitrates (reduce preload → worsens hypotension)
  • ❌ Diuretics (reduce preload → worsens hypotension)
  • ❌ Morphine (venodilation → worsens hypotension)
• If hypotension persists despite fluids: Inotropes (dobutamine preferred over dopamine)

3. Reperfusion: [4]

• Primary PCI (preferred)
  • Urgent cath lab activation
  • Culprit vessel likely RCA
• Drug selection considerations:
  • Aspirin 300mg PO
  • P2Y12 inhibitor (ticagrelor/prasugrel)
  • Unfractionated heparin
  • Caution with GPIIb/IIIa inhibitors (increased bleeding risk if hypotensive)

Monitoring and Follow-Up:

• Most AV blocks in inferior MI are transient (resolve within 48-72 hours as RCA reperfused)
• Permanent pacemaker rarely needed (unlike anterior MI with AV block, which often requires PPM)
• RV function usually recovers within weeks if successfully reperfused

Differentiation from Cardiogenic Shock:

Clinical Pearl: The triad of hypotension, clear lung fields, and elevated JVP in the context of inferior STEMI is pathognomonic for RV infarction. Treatment with nitrates or diuretics can be catastrophic. [1,4]"

---

Scenario 3: Post-MI Complications - New Murmur

Examiner: "A 65-year-old man had an anterior STEMI 4 days ago, treated with primary PCI. He now develops sudden shortness of breath and a new loud systolic murmur. What are your differentials and management?"

Model Answer:

"A new murmur days after MI raises immediate concern for mechanical complications - rare but catastrophic. [12,18]

Differential Diagnosis (New Systolic Murmur Post-MI):

1. Papillary Muscle Rupture (Acute Severe Mitral Regurgitation)
2. Ventricular Septal Rupture (VSR)
3. Free Wall Rupture (may have minimal murmur but presents with tamponade)

Distinguish Based on Clinical and Echo Features: [12,18]

Immediate Management (Both Complications): [12,18]

1. Stabilization:

• ABCDE assessment: Likely respiratory distress, shock
• Oxygen: High-flow; prepare for intubation if respiratory failure
• Invasive monitoring: Arterial line, PA catheter (diagnostic and guides therapy)

2. Medical Temporizing (Bridge to Surgery):

• Afterload reduction: Sodium nitroprusside IV (reduces regurgitant fraction/shunt)
  • "Target: SBP 90-100 mmHg (balance organ perfusion vs reduction of MR/shunt)"
• Inotropic support: Dobutamine (if hypotensive despite afterload reduction)
• Avoid: Excessive diuresis (reduces preload, worsens shock)

3. Mechanical Circulatory Support: [12,18]

• Intra-aortic balloon pump (IABP):
  • Reduces afterload (decreases regurgitant fraction/shunt)
  • Increases diastolic coronary perfusion
  • Temporizing measure until surgery
• Consider Impella or VA-ECMO if IABP insufficient

4. Urgent Echocardiography: [12]

• TTE: First-line; identifies lesion, assesses LV function
• TEE: If TTE inadequate; better visualization of mitral valve, VSR

5. Urgent Cardiac Surgery Consultation: [12,18]

• Both are surgical emergencies
• Timing: Emergent or urgent surgery (ideally within hours)
• Procedures:
  • "Papillary muscle rupture: Mitral valve replacement (repair usually not possible)"
  • "VSR: Patch closure of defect"
• Mortality: 20-50% even with surgery (higher if delayed)

Special Consideration - Free Wall Rupture:

• Sudden hemodynamic collapse, PEA arrest
• Echo: Pericardial effusion, hemopericardium
• Management: Pericardiocentesis (temporizing), emergent surgical repair
• Mortality > 90% (most die before reaching surgery)

Timing and Prognosis: [12,18]

• Peak incidence: 3-5 days post-MI (when myocardial necrosis maximal but scar not yet formed)
• Risk factors: Large MI, anterior MI (for VSR), delayed reperfusion, elderly, female, hypertension
• With medical therapy alone: Mortality > 90%
• With surgery: Mortality 20-50% (high but only chance of survival)
• Timing of surgery: Balance hemodynamic instability (operate urgently) vs increased surgical risk if tissue friable (wait for scar formation if possible)

Key Teaching Points:

• High index of suspicion for mechanical complications if new murmur + hemodynamic deterioration post-MI
• Emergent echo mandatory
• IABP as bridge to surgery
• Multidisciplinary approach: cardiology, cardiac surgery, ICU
• Even with optimal management, mortality remains high [12,18]"

---

Clinical Pearls for Exams

Pearl 1: "Not all chest pain is angina"

• Atypical presentations in elderly, diabetics, women (20-30% of MIs)
• Silent ischemia in diabetics (autonomic neuropathy)
• "Anginal equivalents": dyspnea alone, fatigue, syncope

Pearl 2: "Normal ECG doesn't exclude MI"

• 20-30% of NSTEMIs have normal or non-diagnostic ECG
• Serial ECGs mandatory if clinical suspicion high
• Troponin is the definitive biomarker

Pearl 3: "Troponin rise ≠ MI"

• Elevated troponin indicates myocardial injury (NOT necessarily infarction)
• Rise/fall pattern confirms acute event
• Clinical context + ECG + imaging required for diagnosis

Pearl 4: "Morphine may delay antiplatelet absorption"

• Gastroparesis from morphine slows absorption of oral aspirin, ticagrelor, prasugrel
• Use judiciously; consider alternatives (fentanyl)

Pearl 5: "Oxygen is not benign"

• Hyperoxia may increase infarct size (vasoconstriction, oxidative stress)
• Only give if SpO2 less than 90%
• No routine oxygen in normoxemic patients

Pearl 6: "STEMI mimics exist"

• Takotsubo cardiomyopathy (postmenopausal women, emotional stress, apical ballooning)
• Myocarditis (viral prodrome, elevated troponin, normal coronaries)
• Early repolarization (young, athletic, concave ST-elevation)
• LVH with strain
• Acute pericarditis (diffuse concave ST-elevation, PR-depression)

Pearl 7: "Primary PCI > fibrinolysis, but fibrinolysis > no reperfusion"

• Primary PCI is ideal but not always available
• Fibrinolysis within 3 hours has significant mortality benefit
• Don't delay reperfusion waiting for unavailable PCI

Pearl 8: "Post-MI beta-blockers save lives (if given correctly)"

• DO give: Within 24h if no contraindications
• DON'T give if: cardiogenic shock, decompensated HF, bradycardia, heart block
• Greatest benefit if LVEF less than 40%

Pearl 9: "DAPT adherence is critical"

• Premature discontinuation = leading cause of stent thrombosis
• Stent thrombosis mortality > 50%
• Educate patients: NEVER stop without cardiology consultation

Pearl 10: "Cardiac rehab is underutilized but evidence-based"

• 26% reduction in CV mortality (Cochrane review, 63 RCTs)
• Improves quality of life, exercise capacity, psychological wellbeing
• All post-MI patients should be referred [13]

---

12. Patient/Layperson Explanation

What is a Heart Attack?

A heart attack (acute myocardial infarction) happens when a blood vessel that supplies your heart muscle becomes suddenly blocked, usually by a blood clot. Without blood flow, the part of your heart muscle downstream from the blockage doesn't get oxygen and nutrients, and it starts to die within minutes. Think of your heart as a pump that needs its own blood supply—when one of the supply pipes (coronary arteries) gets blocked, the pump itself gets damaged.

In simple terms: A heart attack is a medical emergency where part of your heart muscle dies because a blood clot blocks a coronary artery. The sooner the blockage is opened, the less damage occurs and the better your recovery.

Why Does It Matter?

Heart attacks are life-threatening. They can cause:

• Death (if not treated quickly or if complications occur)
• Heart failure (your heart becomes too weak to pump effectively)
• Dangerous heart rhythms (irregular heartbeats that can be fatal)

The Good News: With modern treatment, most people survive heart attacks and go on to live normal, active lives. The key is getting help quickly—every minute counts. Prompt treatment can open the blocked artery and save your heart muscle.

How Is It Treated?

1. Emergency Treatment (First Few Hours):

When you arrive at the hospital with a suspected heart attack:

• Immediate medications: You'll get aspirin (stops clots from growing), blood thinners, and pain relief
• ECG (heart tracing): Done within 10 minutes to see which type of heart attack you have
• Blood tests: To measure troponin (a protein released when heart muscle is damaged)

2. Opening the Blocked Artery:

The most important treatment is opening the blocked artery as quickly as possible:

• Angioplasty (primary PCI): The preferred treatment. A doctor inserts a thin tube through your wrist or groin, threads it to your heart, and opens the blockage with a tiny balloon. A small metal mesh tube (stent) is usually placed to keep the artery open. This needs to happen within 90 minutes.

• Clot-busting medication (fibrinolysis): If angioplasty isn't available quickly, you may receive a medication through a drip that dissolves the blood clot. This needs to happen within 30 minutes.

3. Medications (Ongoing):

After your heart attack, you'll need several medications, probably for life:

• Aspirin (usually 75-100mg daily): Keeps your blood from clotting
• Another blood thinner (ticagrelor, prasugrel, or clopidogrel): Usually for 12 months, then reviewed
• Statin (atorvastatin 80mg): Lowers cholesterol and stabilizes plaques in your arteries
• Beta-blocker: Slows your heart rate and helps your heart recover
• ACE inhibitor or ARB: Helps your heart pump more efficiently

4. Lifestyle Changes:

Medications alone aren't enough. You'll need to make important lifestyle changes:

• Stop smoking (the single most important thing you can do)
• Eat a healthy diet (Mediterranean diet, less saturated fat, more fruits and vegetables)
• Exercise regularly (aim for 150 minutes per week; start with cardiac rehab)
• Lose weight if overweight
• Control blood pressure and diabetes
• Manage stress

5. Cardiac Rehabilitation:

You'll be offered cardiac rehabilitation—a supervised exercise and education program. This helps you:

• Safely increase your fitness
• Learn about your condition and medications
• Reduce your risk of another heart attack
• Regain confidence

Evidence shows cardiac rehabilitation reduces your risk of dying by about 25% and improves quality of life.

What to Expect: Recovery Timeline

In the Hospital (2-5 days):

• Monitoring for complications
• Starting medications
• Gentle mobilization (walking)
• Education about your condition

First Few Weeks:

• Gradual increase in activity
• Start cardiac rehab
• Adjust to medications
• Follow-up appointment with your doctor

First 3 Months:

• Continue cardiac rehab
• Gradually return to normal activities
• Most people can return to work by 6-12 weeks
• Echocardiogram to check heart function

Long-Term:

• Medications for life
• Regular check-ups (every 3-6 months initially, then annually)
• Maintain healthy lifestyle
• Most people return to normal activities and have excellent quality of life

When to Seek Help

Call 999 (or your emergency number) IMMEDIATELY if you have:

• Chest pain or discomfort lasting more than a few minutes (especially crushing, pressure-like, or squeezing pain in the center of your chest)
• Pain radiating to your arm, jaw, back, neck, or stomach
• Shortness of breath, with or without chest pain
• Cold sweats, nausea, lightheadedness

Don't delay: The sooner treatment starts, the better your outcome. Don't worry about being embarrassed if it turns out not to be a heart attack—it's always better to get checked.

After Your Heart Attack, Seek Help if:

• Chest pain returns (could be another heart attack or angina)
• Severe shortness of breath, especially lying flat (could be heart failure)
• Swelling in your legs (could be heart failure or medication side effect)
• Dizziness, fainting, very slow or fast heartbeat
• Any new symptoms that concern you

Living Well After a Heart Attack

Can I Live a Normal Life? Yes. With modern treatment and lifestyle changes, most people live full, active lives after a heart attack. Many people say their heart attack was a "wake-up call" that led them to adopt a healthier lifestyle.

Will I Have Another Heart Attack? Your risk is higher than someone who hasn't had a heart attack, but taking your medications, making lifestyle changes, and attending follow-ups greatly reduces this risk. About 90% of people who follow their treatment plan do NOT have another heart attack in the first year.

Can I Exercise? Yes—exercise is essential for recovery. Cardiac rehab will teach you how to exercise safely. Most people can return to their previous level of activity, including sports and sexual activity, after a few weeks.

Can I Drive? Usually, you cannot drive for 1 week after an uncomplicated heart attack (check local regulations). If you drive a commercial vehicle, restrictions may be longer.

Can I Fly? Usually safe after 2-3 weeks for uncomplicated heart attacks; check with your doctor.

Can I Return to Work? Most people return to work within 6-12 weeks, depending on the type of work and recovery.

Remember: A heart attack is serious, but with prompt treatment and commitment to your health, most people recover well and live long, fulfilling lives.

---

13. References

Primary Guidelines

1. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol. 2018;72(18):2231-2264. doi:10.1016/j.jacc.2018.08.1038

2. Bhatt DL, Lopes RD, Harrington RA. Diagnosis and Treatment of Acute Coronary Syndromes: A Review. JAMA. 2022;327(7):662-675. doi:10.1001/jama.2022.0358

3. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111(25):3481-3488.

4. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-177. doi:10.1093/eurheartj/ehx393

5. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(4):e78-e140. doi:10.1016/j.jacc.2012.11.019

Troponin and Biomarkers

6. Rubini Giménez M, Wildi K, Wussler D, et al. Early kinetics of cardiac troponin in suspected acute myocardial infarction. Rev Esp Cardiol (Engl Ed). 2021;74(6):502-509. doi:10.1016/j.rec.2020.04.008

7. Wereski R, Kimenai DM, Taggart C, et al. Cardiac Troponin Thresholds and Kinetics to Differentiate Myocardial Injury and Myocardial Infarction. Circulation. 2021;144(7):528-538. doi:10.1161/CIRCULATIONAHA.121.054302

Risk Stratification

8. Yan AT, Yan RT, Cantor WJ, et al. Relationship between risk stratification at admission and treatment effects of early invasive management following fibrinolysis: insights from the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). Eur Heart J. 2011;32(16):1994-2002. doi:10.1093/eurheartj/ehr008

Dual Antiplatelet Therapy

9. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2016;134(10):e123-e155. doi:10.1161/CIR.0000000000000404

10. Watanabe H, Morimoto T, Natsuaki M, et al. Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial. JAMA Cardiol. 2022;7(4):407-417. doi:10.1001/jamacardio.2021.5244

Heart Failure and Complications

11. Carberry J, Marquis-Gravel G, O'Meara E, et al. Where Are We With Treatment and Prevention of Heart Failure in Patients Post-Myocardial Infarction? JACC Heart Fail. 2024;12(7):1157-1165. doi:10.1016/j.jchf.2024.04.025

12. Damluji AA, van Diepen S, Katz JN, et al. Mechanical Complications of Acute Myocardial Infarction: A Scientific Statement From the American Heart Association. Circulation. 2021;144(2):e16-e35. doi:10.1161/CIR.0000000000000985

Cardiac Rehabilitation

13. Dibben G, Faulkner J, Oldridge N, et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 2021;11(11):CD001800. doi:10.1002/14651858.CD001800.pub4

14. Qin Y, Kumar Bundhun P, Yuan ZL, et al. The effect of high-intensity interval training on exercise capacity in post-myocardial infarction patients: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022;29(3):475-484. doi:10.1093/eurjpc/zwab060

Additional Key References

15. Pollack CV, Amin A, Wang T, et al. Contemporary NSTEMI management: the role of the hospitalist. Hosp Pract (1995). 2020;48(sup1):1-11. doi:10.1080/21548331.2020.1701329

16. Gimbel M, Qaderdan K, Willemsen L, et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Lancet. 2020;395(10233):1374-1381. doi:10.1016/S0140-6736(20)30325-1

17. Kamran H, Jneid H, Kayani WT, et al. Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review. JAMA. 2021;325(15):1545-1555. doi:10.1001/jama.2021.0716

18. Murphy A, Goldberg S. Mechanical Complications of Myocardial Infarction. Am J Med. 2022;135(12):1401-1409. doi:10.1016/j.amjmed.2022.08.017

19. Bahit MC, Kochar A, Granger CB. Post-Myocardial Infarction Heart Failure. JACC Heart Fail. 2018;6(3):179-186. doi:10.1016/j.jchf.2017.09.015

20. Mahadevan K, Sharma D, Walker C, et al. Impact of paramedic education on door-to-balloon times and appropriate use of the primary PCI pathway in ST-elevation myocardial infarction. BMJ Open. 2022;12(2):e046231. doi:10.1136/bmjopen-2020-046231

21. Wang N, Zhang M, Su H, et al. Fibrinolysis is a reasonable alternative for STEMI care during the COVID-19 pandemic. J Int Med Res. 2020;48(10):300060520966151. doi:10.1177/0300060520966151

22. Buske M, Feistritzer HJ, Jobs A, et al. Management of acute coronary syndrome: ESC guidelines 2023. Herz. 2024;49(1):5-14. doi:10.1007/s00059-023-05222-1

23. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018;138(20):e618-e651. doi:10.1161/CIR.0000000000000617

24. Hsieh MJ, Lee CH, Chen CC, et al. Predictive performance of HAS-BLED risk score for long-term survival in patients with non-ST elevated myocardial infarction without atrial fibrillation. J Cardiol. 2017;69(1):136-143. doi:10.1016/j.jjcc.2016.02.005

Risk Stratification and Scores

25. Ferenci T, Hári P, Vájer P, et al. External validation of the GRACE risk score in patients with myocardial infarction in Hungary. Int J Cardiol Heart Vasc. 2023;46:101210. doi:10.1016/j.ijcha.2023.101210

26. Anand A, Cudmore S, Robertson S, et al. Frailty assessment and risk prediction by GRACE score in older patients with acute myocardial infarction. BMC Geriatr. 2020;20(1):102. doi:10.1186/s12877-020-1500-9

27. Fanaroff AC, Rymer JA, Goldstein SA, et al. Does This Patient With Chest Pain Have Acute Coronary Syndrome?: The Rational Clinical Examination Systematic Review. JAMA. 2015;314(18):1955-1965. doi:10.1001/jama.2015.12735

28. Kolovou GD, Katsiki N, Mavrogeni S. Risk Scores After Acute Coronary Syndrome. Angiology. 2017;68(3):185-188. doi:10.1177/0003319716661069

High-Sensitivity Troponin Algorithms

29. Rubini Gimenez M, Boeddinghaus J, Nestelberger T, et al. Implementation of the ESC 0 h/1 h high-sensitivity troponin algorithm for decision-making in the emergency department. Rev Esp Cardiol (Engl Ed). 2023;76(6):468-472. doi:10.1016/j.rec.2023.01.002

30. Bima P, Lopez-Ayala P, Koechlin L, et al. Derivation and Validation of ESC-0/1-h Algorithm for High-Sensitivity Troponin T and I in Cancer Patients. JACC Adv. 2025;4(3):101821. doi:10.1016/j.jacadv.2025.101821

NSTEMI Guidelines and Anticoagulation

31. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289-1367. doi:10.1093/eurheartj/ehaa575

32. Bavishi C, Abbott JD. Anticoagulation in ST-Elevation Myocardial Infarction. Interv Cardiol Clin. 2021;10(3):307-316. doi:10.1016/j.iccl.2021.03.003

Additional Resources

• European Society of Cardiology (ESC): Clinical Practice Guidelines - https://www.escardio.org/Guidelines
• American College of Cardiology (ACC): Guidelines and Clinical Documents - https://www.acc.org/guidelines
• American Heart Association (AHA): Professional Resources - https://professional.heart.org
• British Heart Foundation: Patient Information and Resources - https://www.bhf.org.uk

---

Last Reviewed: 2026-01-10 | MedVellum Editorial Team

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances and local protocols. Always consult appropriate specialists and current guidelines. This information is not a substitute for professional medical advice, diagnosis, or treatment. In case of emergency, always call your local emergency number (999 in UK, 911 in US).